SynthesisFrontiers in medicine2025
Visfatin levels in pulmonary disease: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visfatin has been demonstrated to have pro-inflammatory effects and is involved in several respiratory disorders, including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia. However, there are some inconsistent findings. This study aimed to assess the association between serum visfatin levels and COPD, pneumonia, asthma, interstitial lung disease (ILD), and bronchiectasis. Methods: A systematic review and meta-analysis were conducted following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. PubMed, Scopus, and Web of Science databases were searched. Studies including a healthy control group and measuring serum visfatin in patients with COPD, asthma, pneumonia, bronchiectasis, or ILD were included. Stata 17 was used for data analysis. Results: Fourteen studies were included. None of them were on bronchiectasis. The analysis showed no significant difference between the COPD group and healthy controls in terms of serum visfatin levels (effect size = -0.02, %95CI: [-0.74, 0.69], Conclusion: Circulating levels of visfatin may be associated with pneumonia, but not COPD or asthma. However, there are still few studies on the levels of visfatin in COPD, asthma, and pneumonia patients, and there is a need for further investigation. Systematic Review Registration: PROSPERO, identifier (CRD42023441144).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.